The sponsor of the investigational ophthalmic bevacizumab drug, Ipique, that the European Medicines Agency last year said should not be granted pan-EU marketing approval for treating age-related macular degeneration (AMD) has asked the agency to re-examine its negative recommendation.
If the EMA changes its mind after the re-examination, Ipique could become the first drug containing bevacizumab to be authorized...








